Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2018

Zadra G, Loda M. Metabolic Vulnerabilities of Prostate Cancer: Diagnostic and Therapeutic Opportunities. Cold Spring Harb Perspect Med. 2018;8(10).

Zhai Y, Song W, Zeng J, Zhao Z, Cao Z. A 31-Year-Old Woman with Consecutive Pregnancy Losses. Clin Chem. 2018;64(5):777-780.

Munari E, Zamboni G, Lunardi G, Marchionni L, Marconi M, Sommaggio M, et al. PD-L1 Expression Heterogeneity in Non-Small Cell Lung Cancer: Defining Criteria for Harmonization between Biopsy Specimens and Whole Sections. J Thorac Oncol. 2018;13(8):1113-1120.

Schwartz Z, Bowe RB, Coleman M, Magro CM. Pediatric oral Epstein-Barr virus associated self-remitting CD30+ lymphoproliferative disorder: A distinct entity. Ann Diagn Pathol. 2018;37:57-61.

Nayar R, Barkan GA, Benedict C, Booth C, Chhieng DC, Mody D, et al. Laboratory management curriculum for cytopathology subspecialty training. J Am Soc Cytopathol. 2018;7(2):61-78.

Mottahedeh J, Haffner MC, Grogan TR, Hashimoto T, Crowell PD, Beltran H, et al. CD38 is methylated in prostate cancer and regulates extracellular NAD. Cancer Metab. 2018;6:13.

Magro CM, Kazi N, Sisinger AE. Primary cutaneous histiocytic sarcoma: A report of five cases with primary cutaneous involvement and review of the literature. Ann Diagn Pathol. 2018;32:56-62.

Soshnev AA, Josefowicz SZ, C Allis D. Greater Than the Sum of Parts: Complexity of the Dynamic Epigenome. Mol Cell. 2018;69(3):533.

Shiue K, Cerra-Franco A, Shapiro R, Estabrook N, Mannina EM, Deig CR, et al. Histology, Tumor Volume, and Radiation Dose Predict Outcomes in NSCLC Patients After Stereotactic Ablative Radiotherapy. J Thorac Oncol. 2018;13(10):1549-1559.

Johncilla M, Jessurun J, Brown I, Hornick JL, Bellizzi AM, Shia J, et al. Are Enterocolic Mucosal Mast Cell Aggregates Clinically Relevant in Patients Without Suspected or Established Systemic Mastocytosis? Am J Surg Pathol. 2018;42(10):1390-1395.